Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T

GlobeNewswireApr 24 22:01

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Yahoo FinanceApr 15 21:55

Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.

Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.

Zhitong FinanceApr 9 22:20

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,

BenzingaApr 9 22:01

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

TipRanksApr 9 21:35

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Dow JonesApr 9 20:56